Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Down 23.9% in February

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 1,180,000 shares, a decline of 23.9% from the January 31st total of 1,550,000 shares. Based on an average daily volume of 335,000 shares, the short-interest ratio is presently 3.5 days. Approximately 8.8% of the company’s shares are short sold.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its position in Sensus Healthcare by 30.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company’s stock valued at $2,620,000 after purchasing an additional 88,953 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Sensus Healthcare by 81.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company’s stock valued at $1,039,000 after acquiring an additional 67,269 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Sensus Healthcare by 99.6% during the fourth quarter. Marshall Wace LLP now owns 132,286 shares of the company’s stock valued at $915,000 after acquiring an additional 65,994 shares in the last quarter. Millennium Management LLC lifted its position in Sensus Healthcare by 256.6% in the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company’s stock valued at $590,000 after acquiring an additional 61,403 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Sensus Healthcare in the fourth quarter valued at about $381,000. 25.30% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on SRTS. HC Wainwright increased their price target on Sensus Healthcare from $11.00 to $12.00 and gave the company a “buy” rating in a report on Monday, February 10th. Maxim Group lifted their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Finally, Lake Street Capital began coverage on shares of Sensus Healthcare in a report on Friday, January 31st. They issued a “buy” rating and a $18.00 target price on the stock.

Sensus Healthcare Stock Performance

SRTS opened at $4.69 on Thursday. The firm’s 50-day simple moving average is $6.40 and its 200-day simple moving average is $6.76. Sensus Healthcare has a twelve month low of $2.91 and a twelve month high of $9.33. The firm has a market cap of $76.86 million, a price-to-earnings ratio of 11.73 and a beta of 1.28.

Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. As a group, sell-side analysts anticipate that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.